Safety results and resection rates also appeared encouraging, Davendra P.S. Sohal, MD, MPH, gastrointestinal medical oncologist and director of the clinical genomics program at Cleveland Clinic Taussig Cancer Institute, and colleagues concluded. Read more . . .
Perioperative chemotherapy appeared feasible for patients with resectable pancreatic adenocarcinoma, according to randomized phase 2 study results presented at ASCO Annual Meeting.